The production of the radioisotope molybdenum-99 for medical industry openly in the Research Institute of Atomic Reactors (RIAR) in Dimitrovgrad, Ulyanovsk region.
Molybdenum-99 is the basis for the creation of almost all currently existing radiopharmaceuticals. Opening production will be able to provide 100% of the internal demand of radiological medical institutions in preparation technetium-99, which is used for the diagnosis and treatment of cancer and cardiovascular diseases.
At the first stage of the design production capacity is up to 800 Ci per week, in 2012 the volume of use of the drug will increase to 2,500 Ci per week.
The project for the production of molybdenum is one of the most significant and disruptive innovation in the nuclear center of the Ulyanovsk region. Among other key innovative areas of nuclear Centre — the creation of a multi-RIAR fast research reactor (MBIR).
On MBIR will conduct research and testing of materials for commercial nuclear reactors of the new, fourth generation. It will be the world's only research reactor facility sharing — Scientists from around the world will be able to rent a unit for their research.
It is equally important task of the nuclear centers will be the treatment of patients with cancer. To do this, Dimitrovgrad already started the construction of high-tech center of the Federal Medical Radiology. Construction is scheduled for completion in late 2013.
It is expected that each year there will undergo treatment about 40 thousand people.